Ortho Regenerative Technologies Reports its Third Quarter 2021 Results

Total of $6.7 million raised during current fiscal year through non-brokered private placements, including more than $1.1 million from insiders and employees Ortho-R designated as a Drug/Biologics combination product by the FDA Ortho-R Rotator Cuff tear repair program progressing towards start of US Phase I/II clinical study in early 2021 Company’s shares started trading on… Continue reading Ortho Regenerative Technologies Reports its Third Quarter 2021 Results